Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify the treatment of venous thromboembolism. METHODS: In this randomized, double-blind study, we compared apixaban (at a dose of 10 mg twice daily for 7 days, followed by 5 mg twice daily for 6 months) with conventional therapy (subcutaneous enoxaparin, followed by warfarin) in 5395 patients with acute venous thromboembolism. The primary efficacy outcome was recurrent symptomatic venous thromboembolism or death related to venous thromboembolism. The principal safety outcomes were major bleeding alone and major bleeding plus clinically relevant nonmajor bleeding. RESULTS: The primary efficacy outcome occurred in 59 of 2609 patients (2.3%) in the apixaban group, as compared with 71 of 2635 (2.7%) in the conventional-therapy group (relative risk, 0.84; 95% confidence interval [CI], 0.60 to 1.18; difference in risk [apixaban minus conventional therapy], -0.4 percentage points; 95% CI, -1.3 to 0.4). Apixaban was noninferior to conventional therapy (P<0.001) for predefined upper limits of the 95% confidence intervals for both relative risk (<1.80) and difference in risk (<3.5 percentage points). Major bleeding occurred in 0.6% of patients who received apixaban and in 1.8% of those who received conventional therapy (relative risk, 0.31; 95% CI, 0.17 to 0.55; P<0.001 for superiority). The composite outcome of major bleeding and clinically relevant nonmajor bleeding occurred in 4.3% of the patients in the apixaban group, as compared with 9.7% of those in the conventional-therapy group (relative risk, 0.44; 95% CI, 0.36 to 0.55; P<0.001). Rates of other adverse events were similar in the two groups. CONCLUSIONS: A fixed-dose regimen of apixaban alone was noninferior to conventional therapy for the treatment of acute venous thromboembolism and was associated with significantly less bleeding (Funded by Pfizer and Bristol-Myers Squibb; ClinicalTrials.gov number, NCT00643201).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
In the citing paper
“We conducted a subgroup analysis of the evidence of DOACs vs VKAs 86-97 and found no interaction between the specific agent used and the risk of mortality, PE, symptomatic DVT, or major bleeding.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [86]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Self-citationPulmonary embolism and deep vein thrombosis
Goldhaber, S. Z., & Bounameaux, H. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61904-1 · Cited by 1,054
Farrington, C. P., & Manning, G. (1990) · Statistics in Medicine · doi:10.1002/sim.4780091208 · Cited by 657
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa064247 · Cited by 335
Cited by
Items 101–200 of 1,003
Agnelli, G., Becattini, C., Bauersachs, R., Brenner, B., Campanini, M., Cohen, A., Connors, J., Fontanella, A., Gussoni, G., Huisman, M., et al. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1668523 · Cited by 146
Self-citationCohen, H., Arachchillage, D. J., Middeldorp, S., Beyer‐Westendorf, J., & Kadir, R. A. (2016) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13366 · Cited by 154
Guntupalli, S. R., Brennecke, A., Behbakht, K., Tayebnejad, A., Breed, C., Babayan, L. M., Cheng, G., Ramzan, A. A., Brubaker, L. W., Corr, B. R., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.7410 · Cited by 150
Gómez‐Outes, A., Terleira‐Fernández, A. I., Lecumberri, R., Suárez‐Gea, M. L., & Vargas, E. (2014) · Thrombosis Research · doi:10.1016/j.thromres.2014.06.020 · Cited by 148
Evaluation of Dose-Reduced Direct Oral Anticoagulant Therapy
Barra, M. E., Fanikos, J. R., Connors, J. M., Sylvester, K. W., Piazza, G., & Goldhaber, S. Z. (2016) · The American Journal of Medicine · doi:10.1016/j.amjmed.2016.05.041 · Cited by 150
Kakkos, S. K., Kirkilesis, G. I., & Tsolakis, I. A. (2014) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2014.05.001 · Cited by 138
Miller, C., Dorreen, A. P., Martel, M., Huynh, T. T., & Barkun, A. N. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.031 · Cited by 149
Kushnir, M., Choi, Y., Eisenberg, R., Rao, D., Tolu, S., Gao, J., Mowrey, W., & Billett, H. H. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30086-9 · Cited by 137
Grilz, E., Posch, F., Nopp, S., Königsbrügge, O., Lang, I. M., Klimek, P., Stefan Thurner, A., Pabinger, I., & Ay, C. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab171 · Cited by 143
Lutz, J., Jurk, K., & Schinzel, H. (2017) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s105771 · Cited by 143
“Due to its lower renal elimination apixaban should be preferred in older patients with a GFR between 30 and 60 mL/min.(45)”
Ballestri, S., Romagnoli, E., Arioli, D., Coluccio, V., Marrazzo, A., Athanasiou, A., Girolamo, M. D., Cappi, C., Marietta, M., & Capitelli, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02333-9 · Cited by 150
“Data from RCTs In RCTs of DOACs on patients with VTE (RE-COVER, EINSTEIN-DVT, EINSTEIN-PE, AMPLIFY, Hokusai-VTE), the risk of MB was significantly lower with rivaroxaban (HR 0.54) and apixaban (HR 0.31), while it was similar with dabigatran 150 mg and edoxaban compared to warfarin; cases of ICH were lower with all fou…”
BackgroundInfluentialAndreozzi, G. M., Bignamini, A. A., Davì, G., Palareti, G., Matuška, J., Holý, M., Pawlaczyk-Gabriel, K., Džupina, A., Юрьевич, С. Г., Didenko, Y. P., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.016930 · Cited by 138
Stubbs, M. J., Mouyis, M., & Thomas, M. R. (2018) · BMJ · doi:10.1136/bmj.k351 · Cited by 151
Update on Guidelines for the Management of Cancer-Associated Thrombosis
Streiff, M. B., Abutalib, S. A., Farge, D., Murphy, M. C., Connors, J. M., & Piazza, G. (2020) · The Oncologist · doi:10.1002/onco.13596 · Cited by 143
Evolving use of new oral anticoagulants for treatment of venous thromboembolism
Yeh, C. H., Gross, P. L., & Weitz, J. I. (2014) · Blood · doi:10.1182/blood-2014-03-563056 · Cited by 127
“Rivaroxaban or apixaban may be good choices for patients over the age of 75 with reduced renal function (creatinine clearance of 30-50mL/min), particularly femaleswith lowbodyweight, because the benefit-to-risk profile of these agents in frail patients is superior to that of conventional therapy.(18,27) Dabigatran may…”
BackgroundSelf-citationElsebaie, M. A., van Es, N., Langston, A. A., Buller, H. R., & Gaddh, M. (2019) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14398 · Cited by 142
Self-citationCaldeira, D., Rodrigues, F. B., Barra, M., Santos, A. T., Abreu, D., Gonçalves, N., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2015) · Heart · doi:10.1136/heartjnl-2015-307489 · Cited by 134
Gengler, B. E., Barasch, N. S., & Tellor, K. B. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1905 · Cited by 130
“3 The same exclusion criteria were also used for the study evaluating apixaban in the treatment of acute venous thromboembolism (VTE).(4) Patients with renal dysfunction inherently have a higher risk of bleeding than do those without renal dysfunction; thus, the safety of each anticoagulant should be evaluated in this…”
MethodEffect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa
Vakkalagadda, B. J., Frost, C. E., Byon, W., Boyd, R. A., Wang, J. J. J., Zhang, D., Yu, Z., Dias, C. S., Shenker, A., & LaCreta, F. P. (2016) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-015-0157-9 · Cited by 133
Hillarp, A., Gustafsson, K. M., Faxälv, L., Strandberg, K., Baghaei, F., Fagerberg, I., Berndtsson, M., & Lindahl, T. L. (2014) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12649 · Cited by 120
Prevention, Diagnostics and Treatment of Deep Vein Thrombosis. Russian Experts Consensus
Seliverstov, E. I., Lobastov, K. V., Ilyukhin, Е. А., Apkhanova, T. V., Akhmetzyanov, R. V., Akhtyamov, I. F., Barinov, V., Bakhmetiev, A. S., Belov, M. V., Александрович, Б. С., et al. (2023) · Journal of Venous Disorders · doi:10.17116/flebo202317031152 · Cited by 121
Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays
Flaujac, C., Delavenne, X., Quenet, S., Horellou, M., Laporte, S., Siguret, V., Lecompte, T., & Gouin‐Thibault, I. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-06-0470 · Cited by 116
“Phase III clinical trials with apixaban for treatment of venous thromboembolism have also been completed (4, 5).”
BackgroundRivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location
Janczak, D. T., Mimier, M. K., McBane, R. D., Kamath, P. S., Simmons, B. S., Bott‐Kitslaar, D. M., Lenz, C. J., Vargas, E. R., Hodge, D. O., & Wysokiński, W. E. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.10.007 · Cited by 118
Management of antiphospholipid syndrome
Uthman, I. W., Noureldine, M. H. A., Ruiz‐Irastorza, G., & Khamashta, M. A. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2018-213846 · Cited by 125
Hohnloser, S. H., Fudim, M., Alexander, J. H., Wojdyla, D. M., Ezekowitz, J. A., Hanna, M., Atar, D., Hijazi, Z., Bahit, M. C., Al-Khatib, S. M., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037955 · Cited by 111
Klok, F. A., Kooiman, J., Huisman, M. V., Konstantinides, S., & Lankeit, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00040714 · Cited by 117
Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants
Chan, N., Eikelboom, J. W., & Weitz, J. I. (2016) · Circulation Research · doi:10.1161/circresaha.116.306925 · Cited by 125
Self-citationSafety and effectiveness of apixaban compared to warfarin in dialysis patients
Reed, D. R., Palkimas, S., Hockman, R. H., Abraham, S., Le, T. M., & Maitland, H. S. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12083 · Cited by 115
Portal vein thrombosis in cirrhosis: Controversies and latest developments
Harding, D., Perera, M. T. P. R., Chen, F. E., Olliff, S. P., & Tripathi, D. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i22.6769 · Cited by 121
Ruff, C. T., Giugliano, R. P., & Antman, E. M. (2016) · Circulation · doi:10.1161/circulationaha.116.021831 · Cited by 116
Vascular Thoracic Outlet Syndrome
Hussain, M. A., Aljabri, B. A., & Al-Omran, M. A. (2015) · Seminars in Thoracic and Cardiovascular Surgery · doi:10.1053/j.semtcvs.2015.10.008 · Cited by 108
“Venous TOS series have generally only reported warfarin as the anticoagulation agent of choice, although alternative agents such as oral factor Xa inhibitors may be considered given their efficacy in the treatment of venous thrombosis.(32,33)”
BackgroundPrevention and Management of the Post-Thrombotic Syndrome
Makedonov, I., Kahn, S. R., & Galanaud, J. ‐. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040923 · Cited by 112
Ageno, W., Vedovati, M. C., Cohen, A. T., Huisman, M. V., Bauersachs, R. M., Gussoni, G., Becattini, C., & Agnelli, G. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1720975 · Cited by 114
Self-citationLevy, J. H., Spyropoulos, A. C., Samama, C. M., & Douketis, J. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.06.014 · Cited by 119
“The rate of major bleeding is also generally similar; however, in clinical trials of apixaban for VTE treatment and rivaroxaban for PE treatment, significant (69% and 51%) relative risk reductions in major bleeding compared with standard therapy have been demonstrated (18,31).”
MethodResultInfluentialAntagonists of Vitamin K—Popular Coumarin Drugs and New Synthetic and Natural Coumarin Derivatives
Kasperkiewicz, K., Ponczek, M. B., Owczarek, J., Guga, P., & Budzisz, E. (2020) · Molecules · doi:10.3390/molecules25061465 · Cited by 122
Noble, S., Matzdorff, A. C., Maraveyas, A., Holm, M., & Pisa, G. (2015) · Haematologica · doi:10.3324/haematol.2015.127126 · Cited by 106
Caldeira, D., Barra, M., Santos, A. T., Abreu, D., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Heart · doi:10.1136/heartjnl-2013-305288 · Cited by 112
CSAR 2014: A Benchmark Exercise Using Unpublished Data from Pharma
Carlson, H. A., Smith, R. D., Damm-Ganamet, K. L., Stuckey, J. A., Ahmed, A., Convery, M. A., Somers, D. O., Kranz, M., Elkins, P. A., Cui, G., et al. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00523 · Cited by 103
Acute pulmonary embolism: a concise review of diagnosis and management
Rayner, M., Darvall, J. N., & Hammerschlag, G. (2019) · Internal Medicine Journal · doi:10.1111/imj.14145 · Cited by 120
Douxfils, J., Buckinx, F., Mullier, F., Minet, V., Rabenda, V., Reginster, J., Hainaut, P., Bruyère, O., & Dogné, J. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.113.000515 · Cited by 108
Mantha, S. H., Laube, E., Miao, Y., Sarasohn, D. M. M., Parameswaran, R., Stefanik, S., Brar, G. S., Samedy, P., Wills, J., Harnicar, S. J., et al. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1429-1 · Cited by 104
The evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed Central · doi:10.2450/2015.0096-15 · Cited by 127
Obesity and lower limb venous disease – The epidemic of phlebesity
Davies, H., Popplewell, M. A., Singhal, R., Smith, N., & Bradbury, A. W. (2016) · Phlebology The Journal of Venous Disease · doi:10.1177/0268355516649333 · Cited by 102
“A sub-group analysis of the AMPLIFY study demonstrated no effect of weight on efficacy but did show lower major bleeding rates with apixiban when compared to warfarin in patients >100 kg.(60)”
BackgroundKreuziger, L. B., Jaffray, J., & Carrier, M. (2017) · Thrombosis Research · doi:10.1016/j.thromres.2017.07.002 · Cited by 102
Chronic complications of venous thromboembolism
Winter, M. P., Schernthaner, G.-H., & Lang, I. M. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13741 · Cited by 116
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis
Caldeira, D., Barra, M., Pinto, F. J., Ferreira, J. J., & Costa, J. N. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7462-0 · Cited by 111
Deep Vein Thrombosis of the Upper Extremity
Heil, J., Miesbach, W., Vogl, T. J., Bechstein, W. O., & Reinisch, A. (2017) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2017.0244 · Cited by 122
Castellucci, L. A., Shaw, J. R., van der Salm, K., Erkens, P. M. G., Gal, G. L., Petrcich, W., & Carrier, M. (2015) · Thrombosis Research · doi:10.1016/j.thromres.2015.07.007 · Cited by 100
Woller, S. C., Stevens, S. M., Kaplan, D. A., Branch, D. W., Aston, V. T., Wilson, E. L., Gallo, H. M., Johnson, E., Rondina, M. T., Lloyd, J. F., et al. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615615960 · Cited by 106
Evaluation of bleeding in patients receiving direct oral anticoagulants
Hellenbart, E. L., Faulkenberg, K. D., & Finks, S. W. (2017) · Vascular Health and Risk Management · doi:10.2147/vhrm.s121661 · Cited by 112
Gu, Z., Wei, A., Zhang, C., Wang, X., Zhang, L., Shen, L., Li, Z., Pan, M.-M., Liu, X.-Y., Pu, J., et al. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.056 · Cited by 111
Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children
Brandão, L. R., Albisetti, M., Halton, J., Bomgaars, L. R., Chalmers, E. A., Mitchell, L. G., Nurmeev, I. N., Svirin, P., Kuhn, T., Zapletal, O., et al. (2019) · Blood · doi:10.1182/blood.2019000998 · Cited by 105
Dufrost, V., Risse, J., Zuily, S., & Wahl, D. G. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0623-7 · Cited by 99
Advantages and limitations of the new anticoagulants
Schulman, S. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12138 · Cited by 104
The diagnosis and treatment of venous thromboembolism in Asian patients
Wang, K.-L., Yap, E. S., Goto, S., Zhang, S., Siu, C., & Chiang, C. (2018) · Thrombosis Journal · doi:10.1186/s12959-017-0155-z · Cited by 104
“Overall, apixaban was found to be noninferior to the conventional therapy, with respect to recurrent VTE, and had a significant lower risk of major or CRNM bleeding [119].”
BackgroundClinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries
Wheelock, K. M., Ross, J. S., Murugiah, K., Lin, Z., Krumholz, H. M., & Khera, R. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.37288 · Cited by 104
Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor
Bounameaux, H., & Camm, A. J. (2014) · Drugs · doi:10.1007/s40265-014-0261-1 · Cited by 105
Ndumele, C. E., Rodríguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M. S., Bangalore, S., Bozkurt, B., Breathett, K. K., Clarke, S. L., et al. (2026) · Circulation · doi:10.1161/cir.0000000000001453 · Cited by 160
Direct‐acting oral anticoagulants: pharmacology, indications, management, and future perspectives
Gómez‐Outes, A., Suárez‐Gea, M. L., Lecumberri, R., Terleira‐Fernández, A. I., & Vargas, E. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12610 · Cited by 112
Jun, M., Lix, L. M., Durand, M., Dahl, M., Paterson, J. M., Dormuth, C. R., Ernst, P., Yao, S., Renoux, C., Tamim, H., et al. (2017) · BMJ · doi:10.1136/bmj.j4323 · Cited by 107
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
Geldhof, V., Vandenbriele, C., Verhamme, P. B., & Vanassche, T. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-21 · Cited by 98
Hakeam, H. A., & Al-Sanea, N. A. (2017) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1465-x · Cited by 102
Chaudhary, R., Singh, A., Chaudhary, R., Bashline, M. J., Houghton, D. E., Rabinstein, A. A., Adamski, J., Arndt, R., Ou, N. N., Rudis, M. I., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.40145 · Cited by 98
“SAH SDH Others (IPH/IVH/ICerH) Traumatic ICH Anticoagulation reversalb Mortality TE events 4-Factor PCC Grandhi et al,24 2015 4/18 (22) 4/18 (22) 12/18 (67) 8/18 (44) 17/18 (94) 6/18 (33) 1/18 (6) Majeed et al,25 2017 NR NR NR NR 43/59 (73) 13/59 (22) 3/59 (5) Gerner et al,8 2018 NR NR NR NR 61/94 (65) NR NR Schulman…”
Stefano, V. D., Ruggeri, M., Cervantes, F., Álvarez‐Larrán, A., Iurlo, A., Randi, M. L., Elli, E. M., Finazzi, M. C., Finazzi, G., Zetterberg, E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.85 · Cited by 98
Steffel, J., Verhamme, P. B., Potpara, T., Albaladejo, P., Antz, M., Desteghe, L., Hæusler, K. G., Oldgren, J., Reinecke, H., Roldán, V., et al. (2018) · Kardiologia Polska · doi:10.5603/kp.2018.0180 · Cited by 108
Venous thromboembolism: Recent advancement and future perspective
Yamashita, Y., Morimoto, T., & Kimura, T. (2021) · Journal of Cardiology · doi:10.1016/j.jjcc.2021.08.026 · Cited by 106
The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis
Naymagon, L., Tremblay, D. A., Zubizarreta, N. J., Moshier, E. L., Troy, K. M., Schiano, T. D., & Mascarenhas, J. O. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001310 · Cited by 95
“This controversy has its roots in the foundational clinical trials which established the use of DOACs for PE/DVT, as they included no patients with any type of SVT.(10-13) A decade after their publication data remain sparse and composed largely of individual case reports and limited case series.”
BackgroundInfluentialSafety of direct oral anticoagulant exposure during pregnancy: a retrospective cohort study
Beyer‐Westendorf, J., Tittl, L., Bistervels, I. M., Middeldorp, S., Schaefer, C., Paulus, W. E., Thomas, W., Kemkes‐Matthes, B., Marten, S., & Bornhäuser, M. (2020) · The Lancet Haematology · doi:10.1016/s2352-3026(20)30327-6 · Cited by 95
Wolf, S. J., Hahn, S. A., Nentwich, L. M., Raja, A. S., Silvers, S. M., & Brown, M. D. (2018) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2018.03.006 · Cited by 98
DOACs – advances and limitations in real world
Lee, L. H. (2016) · Thrombosis Journal · doi:10.1186/s12959-016-0111-3 · Cited by 96
“Table 1 Pharmacological properties of the DOACs Dabigatran [9, 38] Rivaroxaban [9, 40, 41] Apixaban [9, 37] Edoxaban [9, 39] Target Factor IIa Factor Xa Factor Xa Factor Xa Half-life (hour) 12-17 5-9 12 6-10 Time to peak effect (hour) 1-3 2-4 1-3 1-2 Renal clearance as unchanged drug (”
BackgroundInfluentialBleeding complications during anticoagulant treatment in patients with cancer
Kamphuisen, P. W., & Beyer‐Westendorf, J. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50009-6 · Cited by 95
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Mantha, S. H., & Ansell, J. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1102-5 · Cited by 92
Kulka, H. C., Zeller, A., Fornaro, J., Wuillemin, W. A., Konstantinides, S., & Christ, M. (2011) · Thieme eBooks · doi:10.1055/b-0034-84633 · Cited by 90
Apixaban and dalteparin in active malignancy associated venous thromboembolism: The ADAM VTE Trial
Loprinzi, C. L., Ashrani, A. A., Botero, J. P., Leon-Ferre, R. A., Henkin, S., Lenz, C. J., Le‐Rademacher, J. G., Wysokiński, W. E., & McBane, R. D. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0193 · Cited by 93
“The AMPLIFY investigators randomized 5395 patients with acute VTE to either apixaban (10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months) or enoxaparin/warfarin (28).”
Vasanthamohan, L., Boonyawat, K., Chai‐Adisaksopha, C., & Crowther, M. A. (2018) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.14156 · Cited by 93
Goldhaber, S. Z., Eriksson, H., Kakkar, A., Schellong, S., Feuring, M., Fraessdorf, M., Kreuzer, J., Schueler, E., & Schulman, S. (2016) · Vascular Medicine · doi:10.1177/1358863x16668588 · Cited by 89
Piran, S., Traquair, H., Chan, N., Bhagirath, V. C., & Schulman, S. (2018) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12146 · Cited by 94
Nopp, S., Kraemmer, D., & Ay, C. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.903029 · Cited by 92
When Direct Oral Anticoagulants Should Not Be Standard Treatment
Bejjani, A., Khairani, C. D., Assi, A. A., Piazza, G., Sadeghipour, P., Talasaz, A. H., Fanikos, J. R., Connors, J. M., Siegal, D. M., Barnes, G. D., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.10.038 · Cited by 98
Self-citationHow I treat central venous access device–related upper extremity deep vein thrombosis
Rajasekhar, A., & Streiff, M. B. (2017) · Blood · doi:10.1182/blood-2016-08-693671 · Cited by 94
New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations
Wang, Y., & Bajorek, B. V. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0061-0 · Cited by 97
Jaber, W. A., Fong, P. P., Weisz, G., Lattouf, O. M., Jenkins, J. S., Rosenfield, K., Rab, T., & Ramee, S. R. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.12.024 · Cited by 88
Cohen, A. T., Gitt, A. K., Bauersachs, R. M., Fronk, E., Laeis, P., Mismetti, P., Monréal, M., Willich, S. N., Bramlage, P., Agnelli, G., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-10-0793 · Cited by 98
Self-citationNew oral anticoagulants and regional anaesthesia
Benzon, H. T., Avram, M. J., Green, D., & Bonow, R. O. (2013) · British Journal of Anaesthesia · doi:10.1093/bja/aet401 · Cited by 93
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism
Eikelboom, J. W., Chan, N., & Bhagirath, V. C. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s63060 · Cited by 95
Update on the management of venous thromboembolism
Bartholomew, J. R. (2017) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.84.s3.04 · Cited by 91
Ueshima, S., Hira, D., Fujii, R., Kimura, Y., Tomitsuka, C., Yamane, T., Tabuchi, Y., Ozawa, T., Itoh, H., Horie, M., et al. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000294 · Cited by 85
Makam, R. C. P., Hoaglin, D. C., McManus, D. D., Wang, V., Gore, J. M., Spencer, F. A., Pradhan, R., Tran, H. V., Yu, H., & Goldberg, R. J. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197583 · Cited by 89
Dawwas, G. K., Brown, J., Dietrich, E., & Park, H. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30191-1 · Cited by 84
Grandhi, R., Newman, W. C., Zhang, X., Harrison, G. L., Moran, C. C., Okonkwo, D. O., & Ducruet, A. F. (2015) · World Neurosurgery · doi:10.1016/j.wneu.2015.08.042 · Cited by 87
Nisio, M. D., Bleker, S. M., Segers, A. E. M., Mercuri, M. F., Schwocho, L. R., Kakkar, A. K., Weitz, J. I., Beyer‐Westendorf, J., Boda, Z., Carrier, M., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-06-0452 · Cited by 83
Self-citationBritish Thoracic Society Guideline for the initial outpatient management of pulmonary embolism (PE)
Howard, L., Barden, S., Condliffe, R. A., Connolly, V. M., Davies, C. W. H., Donaldson, J., Everett, B., FREE, C. M., Horner, D. E., Hunter, L. J., et al. (2018) · Thorax · doi:10.1136/thoraxjnl-2018-211539 · Cited by 91
Kaikita, K., Hosokawa, K., Dahlen, J. R., & Tsujita, K. (2019) · Thrombosis and Haemostasis · doi:10.1055/s-0039-1693411 · Cited by 87
Nakamura, M., Yamada, N., & Ito, M. (2015) · Journal of Cardiology · doi:10.1016/j.jjcc.2015.03.012 · Cited by 92
“The limitations of warfarin have stimulated the development of nonvitamin K antagonist oral anticoagulants (NOACs) for the treatment of VTE [10–13] among other indications.”
BackgroundRecent advances in the discovery and development of factor XI/XIa inhibitors
Al‐Horani, R. A., & Afosah, D. K. (2018) · Medicinal Research Reviews · doi:10.1002/med.21503 · Cited by 85
Tittl, L., Endig, S., Marten, S., Reitter, A., Beyer-Westendorf, I., & Beyer‐Westendorf, J. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2018.03.060 · Cited by 86
Direct Oral Anticoagulants in Patients With Active Cancer
Sabatino, J., Rosa, S. D., Polimeni, A., Sorrentino, S., & Indolfi, C. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.06.001 · Cited by 94
Cancer and Venous Thromboembolic Disease: From Molecular Mechanisms to Clinical Management
Donnellan, E., Kevane, B., Bird, B., & Áinle, F. N. (2014) · Current Oncology · doi:10.3747/co.21.1864 · Cited by 91
Thrombosis in cancer patients: etiology, incidence, and management
Sheth, R. A., Niekamp, A., Quencer, K. B., Shamoun, F. E., Knuttinen, M.-G., Naidu, S., & Öklü, R. (2017) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2017.11.02 · Cited by 80
“Dabigatran, rivaroxaban, and apixaban have been studied for acute VTE in the general population and were found to be non-inferior to vitamin K antagonists in phase III clinical trials (29-32).”
Background
Metadata
- Authors
- Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., & Weitz, J. I.
- Affiliations
- University of Perugia (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- King's College Hospital (GB)
- Pfizer (United States) (US)
- Flinders University (AU)
- University of Oklahoma Health Sciences Center (US)
- Thrombosis and Atherosclerosis Research Institute (CA)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-29
- Volume
- 369
- Issue
- 9
- Pages
- 799-808
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2166402206
- Cited by
- 2,324
- References
- 13
- Citations by year
- 2026: 109 · 2025: 101 · 2024: 134 · 2023: 134 · 2022: 162 · 2021: 193 · 2020: 224 · 2019: 193 · 2018: 213 · 2017: 191 · 2016: 234 · 2015: 198 · 2014: 184 · 2013: 51
- FWCI
- 194.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, acute venous thromboembolism, factor Xa inhibitors, oral anticoagulation, enoxaparin, warfarin, recurrent venous thromboembolism, major bleeding, non-inferiority, fixed-dose regimen, direct oral anticoagulants, anticoagulation duration, venous thromboembolism
- MeSH terms
- Acute Disease, Administration, Oral, Adult, Aged, Anticoagulants, Double-Blind Method, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Pyrazoles, Pyridones, Warfarin, Treatment Outcome, Enoxaparin, Kaplan-Meier Estimate, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.